Category: Prescription Drugs
Prescription Drugs market research reports by Euromonitor International
-
Rx/Reimbursement Adult Incontinence in Belgium
Value sales of prescription (RX) and reimbursement adult incontinence products increased in 2024, driven by several key factors. Firstly, Belgium's aging population continued to create consistent demand for these products. Additionally, the rising need for reimbursement for adult incontinence was ex ... Read More
-
Rx/Reimbursement Adult Incontinence in Spain
In 2024, reimbursement adult incontinence saw significant sales growth in Spain. The Spanish healthcare system has adopted a clear strategy by prioritising reimbursement for products specifically designed to manage severe incontinence. This framework reflects not only a commitment to improving patie ... Read More
-
Rx/Reimbursement Adult Incontinence in Sweden
RX/reimbursement adult incontinence saw steady growth in value and volume terms in 2024. Value growth was primarily driven by two key factors: Sweden’s ageing population and the rising prevalence of obesity and type 2 diabetes. A strong correlation exists between age, underlying health conditions an ... Read More
-
Rx/Reimbursement Adult Incontinence in Poland
In 2024, Rx/reimbursement adult incontinence in Poland continued to post healthy retail volume and current value growth, albeit slower than in 2023 and other years of the review period. As in the retail sphere, demand increased alongside a growing number of consumers in older cohorts, who are more l ... Read More
-
Rx/Reimbursement Adult Incontinence in Slovakia
The landscape of Rx/reimbursement adult incontinence in Slovakia underwent notable changes in 2024 due to regulatory adjustments. From April 2024, new legislation was introduced to refine the prescription process, mandating that doctors indicate the specific level of incontinence on a designated vou ... Read More
-
Rx/Reimbursement Adult Incontinence in Hungary
Current value sales growth of Rx/reimbursement adult incontinence products in Hungary in 2024 was significantly higher compared to retail adult incontinence products. as local consumers could be reimbursed by up to 80% by insurance companies. Doctors determine the appropriate payment group for each ... Read More
-
Rx/Reimbursement Adult Incontinence in Norway
Value sales of RX/reimbursement adult incontinence increased in 2024, driven by an ageing population and a rising obesity rate. The natural expansion of the potential user base contributed to steady demand, while growing health consciousness and hygiene awareness further encouraged individuals to se ... Read More
-
Rx/Reimbursement Adult Incontinence in Denmark
Value sales of RX/reimbursement adult incontinence grew in 2024 in Denmark, supported by the ageing population. It is estimated that around 80% of reimbursement recipients are aged 65 and older, a group that is expanding as life expectancy increases. The ageing population, coupled with rising obesit ... Read More
-
Rx/Reimbursement Adult Incontinence in the Czech Republic
Rx/reimbursement adult incontinence saw volume and value growth in the Czech Republic in 2024. The growth of the category is being fuelled not just by the ageing population but also by more information about Rx rights and reimbursements via magazines and pharmacies. Since 1 January 2024, the VAT rat ... Read More
-
Rx/Reimbursement Adult Incontinence in the Netherlands
Value sales of RX/reimbursement adult incontinence increased modestly in 2024, but negative volume growth continued to exert downward pressure on overall performance. Many consumers opted to purchase incontinence products through retail channels or e-commerce platforms rather than rely on reimbursed ... Read More
-
Rx/Reimbursement Adult Incontinence in Colombia
Despite significant challenges within Colombia’s healthcare system – including government interventions affecting major EPS providers such as Sanitas, Nueva EPS, and Famisanar, as well as the financial struggles prompting Sura and Compensar to request withdrawal from the system – Rx/reimbursement in ... Read More
-
Rx/Reimbursement Adult Incontinence in Italy
Rx/reimbursement adult incontinence continued to decline in both volume and current value terms in Italy in 2024 as the National Sanitary System lowered budgets to tackle the country’s massive debt. The basic comfort of these products, coupled with growing consumer acceptance of partial out-of-pocke ... Read More
-
Rx/Reimbursement Adult Incontinence in the US
Rx/reimbursement adult incontinence in the US maintained stable volume and current value growth in 2024. Nevertheless, post-pandemic, Medicaid disenrollment was underway, after three years of continuous enrolment. During the pandemic, states operated under a policy of continuous enrolment, which off ... Read More
-
Rx/Reimbursement Adult Incontinence in France
Value sales of Rx/reimbursement adult incontinence increased in 2024 in France, as did volume sales. In France, these products sustained a positive growth trend over the year, driven by their essential nature, which makes them difficult to substitute. Demand stems largely from an ageing population a ... Read More
-
Rx/Reimbursement Adult Incontinence in Germany
Value sales of rx/reimbursement adult incontinence in Germany continued to rise in 2024, mainly driven by ongoing high production costs and persistent inflation. On the other hand, retail volume sales continued to slowly decline. The demand for rx/reimbursement adult incontinence in Germany is prima ... Read More
-
Pharmaceuticals in Mexico: ISIC 2423
PPI Euromonitor International's Industrial reports provide a 360 degree view of an industry. The Industrial market report offers a comprehensive guide to the size and shape of the Pharmaceuticals: ISIC 2423 market at a national level. It provides the latest retail sales data, allowing you to identif ... Read More
-
Pharmaceuticals in Canada: ISIC 2423
Pharmaceuticals in Canada: ISIC 2423 PPI Euromonitor International's Industrial reports provide a 360 degree view of an industry. The Industrial market report offers a comprehensive guide to the size and shape of the Pharmaceuticals: ISIC 2423 market at a national level. It provides the latest retai ... Read More
-
Analgesics in Germany
Analgesics in Germany Analgesics in Germany is experiencing moderate positive growth in current value terms in 2024. Challenging economic and social issues tend to increase demand for effective pain management solutions. German consumers are also increasingly willing to invest in more advanced analg ... Read More
-
Pharmaceuticals in Germany: ISIC 2423
Pharmaceuticals in Germany: ISIC 2423 PPI Euromonitor International's Industrial reports provide a 360 degree view of an industry. The Industrial market report offers a comprehensive guide to the size and shape of the Pharmaceuticals: ISIC 2423 market at a national level. It provides the latest reta ... Read More
-
Pharmaceuticals in the US: ISIC 2423
Pharmaceuticals in the US: ISIC 2423 PPI Euromonitor International's Industrial reports provide a 360 degree view of an industry. The Industrial market report offers a comprehensive guide to the size and shape of the Pharmaceuticals: ISIC 2423 market at a national level. It provides the latest retai ... Read More
-
Pharmaceuticals in Japan: ISIC 2423
Pharmaceuticals in Japan: ISIC 2423 PPI Euromonitor International's Industrial reports provide a 360 degree view of an industry. The Industrial market report offers a comprehensive guide to the size and shape of the Pharmaceuticals: ISIC 2423 market at a national level. It provides the latest retail ... Read More
-
Pharmaceuticals in the United Kingdom: ISIC 2423
Pharmaceuticals in the United Kingdom: ISIC 2423 Euromonitor International's Industrial reports provide a 360 degree view of an industry. The Industrial market report offers a comprehensive guide to the size and shape of the Pharmaceuticals: ISIC 2423 market at a national level. It provides the late ... Read More
-
Cough, Cold and Allergy (Hay Fever) Remedies in the US
Cough, Cold and Allergy (Hay Fever) Remedies in the US Cough, cold and allergy remedies is set to see a single-digit retail current value decline in the US in 2024, which is a continuation of normalisation after the extreme double-digit growth brought about by the “tripledemic” in 2022. While most p ... Read More
-
Rx/Reimbursement Adult Incontinence in Brazil
Rx/Reimbursement Adult Incontinence in Brazil Rx/reimbursement adult incontinence continued to experience steady volume and current value growth in Brazil in 2023, despite economic challenges. However, the category faced significant hurdles, particularly in health units, where a shortage of products ... Read More
-
Rx/Reimbursement Adult Incontinence in Austria
Rx/Reimbursement Adult Incontinence in Austria Rx/reimbursement adult incontinence recorded strong growth in current value terms in 2023 continuing the trend of the previous year. However, this was mainly due to prevailing inflationary pressures, as rising raw material, production and transport cost ... Read More
Research Assistance
